scholarly journals Therapeutic Effects of Recombinant Human Epidermal Growth Factor (rhEGF) in a Murine Model of Concurrent Chemo- and Radiotherapy-Induced Oral Mucositis

2010 ◽  
Vol 51 (5) ◽  
pp. 595-601 ◽  
Author(s):  
Seung-Hee RYU ◽  
Ki Mun KANG ◽  
Soo Young MOON ◽  
Gyu Young CHAI ◽  
Joon Pio HONG ◽  
...  
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Oral Mucositis ◽  
Murine Model ◽  
Therapeutic Effects ◽  
Human Epidermal Growth Factor ◽  
Epidermal Growth

scholarly journals Microencapsulated Recombinant Human Epidermal Growth Factor Ameliorates Osteoarthritis in a Murine Model

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Shih-Chao Lin ◽  
Xiang Zhang ◽  
Shiow-Yi Chen ◽  
Chi-Chien Lin ◽  
Yen-Shuo Chiu
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Platelet Rich Plasma ◽  
Therapeutic Effects ◽  
Inflammatory Disorder ◽  
Chronic Inflammatory Disorder ◽  
Human Epidermal Growth Factor ◽  
Age Related ◽  
Epidermal Growth

Osteoarthritis, a highly age-related and chronic inflammatory disorder with cartilage loss, causes patients difficultly in movement; there is no efficient and sustainable remedy for osteoarthritis currently. Although hyaluronic acid (HA) and platelet-rich plasma (PRP) have been used to alleviate osteoarthritis, the effects could be short and multiple injections might be required. To address this issue, we exploited the property of chitosan to encapsulate recombinant human epidermal growth factor and obtained microencapsulated rhEGF (Me-rhEGF). In the current study, we induced the osteoarthritis-like symptoms with monosodium iodoacetate (MIA) in rats and investigated the therapeutic effects of Me-rhEGF. Following administration of HA/Me-rhEGF in vivo, we observed that the total Mankin scores, cartilage oligomeric protein, C-telopeptide of type II collagen, IL-1β, IL-6, IL-17A, and TNF-α cytokines, nitric oxide, and prostaglandin E2 expressions were significantly inhibited. Our results also strongly indicate that individual use of HA or rhEGF slightly decreased the inflammation and restored the destructive joint structure, but was not as drastic as seen in the HA/Me-rhEGF. Moreover, HA/Me-rhEGF profoundly reduced cartilage destruction and proteoglycan loss and downregulated matrix metalloproteinase expressions. These findings reveal that the treatment of HA/Me-rhEGF could be more beneficial than the use of single HA or rhEGF in reliving osteoarthritis and demonstrate the therapeutic application of microencapsulation technology in difficult joint disorders. In essence, we believe that the Me-rhEGF could be promising for further research and development as a clinical treatment against osteoarthritis.

Sign in / Sign up

Export Citation Format

Share Document